Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer

Estrogen Receptor‐Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance

(2018) Adam M. Brufsky et al.   ONCOLOGIST

Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer

(2017) Giuseppe Curigliano et al.   Expert Opinion on Drug Metabolism & Toxicology

Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer

(2017) Zongbi Yi et al.   Journal of Breast Cancer

Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2− and ER+HER2+) breast cancers

(2017) Noriko Kanaya et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation

(2017) Sami I. Bashour et al.   Journal of Cancer

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells

(2017) Mara A. Bonelli et al.   NEOPLASIA

Defining the optimal sequence for the systemic treatment of metastatic breast cancer

(2016) J. A. Mestres et al.   Clinical & Translational Oncology

A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer

(2016) C. X. Ma et al.   CLINICAL CANCER RESEARCH

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt

(2016) Jinfang Zhang et al.   MOLECULAR CELL

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

(2016) C Yang et al.   ONCOGENE

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer

(2015) C. X. Ma et al.   CLINICAL CANCER RESEARCH

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

(2014) Ingrid A. Mayer et al.   JOURNAL OF CLINICAL ONCOLOGY

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers

(2014) Elisavet Paplomata et al.   Therapeutic Advances in Medical Oncology

Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts

(2013) Alexandre Ingels et al.   INTERNATIONAL JOURNAL OF CANCER

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110  Inhibitors in PIK3CA-Mutant Breast Cancer

(2013) M. Elkabets et al.   Science Translational Medicine

Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors

(2011) E. Vilar et al.   MOLECULAR CANCER THERAPEUTICS

“Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?

(2010) Nadia Margariti et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinical significance of estrogen receptor phosphorylation

(2010) L. C. Murphy et al.   ENDOCRINE-RELATED CANCER

Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway

(2009) Edoardo Missiaglia et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines

(2009) Selma Masri et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY